125 Cambridgepark Drive Cambridge, MA 02140 +1 877.848.9903
Real world data sources further enhances the commercial value and scale of patient-centered analytics
CAMBRIDGE, MA. – March 10, 2020 - IPM.ai, an emerging leader in discovering ideal patient populations though the use of machine learning and artificial intelligence, today announced that it has recently onboarded multiple new health data assets, bringing total covered lives to over 300 million and significantly expanding coverage in both primary care and specialty markets. The resulting combination of IPM.ai's medical and prescription claims data, taken together with its existing Social Determinants of Health (SDOH) data, is now unmatched in the industry. "With these exciting new enhancements, we believe that our medical claims coverage -which is increasingly the anchor of patient-centered analytics in specialty markets - is best in class" said Jonathan Woodring, Executive Vice President and General Manager of IPM.ai. "In most emerging specialty markets the very basics of commercialization efforts are ambiguous due to traditionalRx data being insufficient to provide a complete view. Quantifying the total size of the market, understanding the patient journey, determining appropriate physician and patient audiences and developing appropriate engagement strategies for physicians and patients remains an ongoing challenge in these markets. Our expanded asset allows us to continue our efforts to solve for these gaps, and subsequently improve the health outcomes for patients at scale." Additionally, the newly expanded data set improves parent company Swoop's ability to create highly effective health audience segments. As the only consumer health data-oriented member of the Network Advertising Initiative (NAI), Swoop provides biotech and pharmaceutical clients with an effective channel to commercialize IPM.ai's patient-centered analytics via audience-targeted advertising.
IPM.ai is an Insights as a Service (IaaS) company that empowers the world’s leading life sciences brands to better understand and improve the lives of patients through the research, development and commercialization of new therapies and modalities of care for specialty and rare disease. IPM.ai’s system of insight streamlines patient discovery, treatment journey mapping, referral network intelligence, key opinion leader identification, market segmentation and adherence modeling by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world data, social determinants of health and outcomes research pool of over 300 million de-identified patients.
Chief Marketing Officer
Leveraging the power of RWD and AI to identify, engage and activate ideal patient populations who could benefit from new therapies and modalities of care.
Subscribe to our newsletter for the latest company updates, industry developments, and media coverage.